The additive effect of p53 Arg72Pro and RNASEL Arg462Gln genotypes on age of disease onset in Lynch syndrome patients with pathogenic germline mutations in MSH2 or MLH1

Cancer Letters

Volumn 252, Issue 1, 2007, Pages 55-64

  Krüger, Stefan ^a   Engel, Christoph ^b   Bier, Andrea ^a   Silber, Ann Sophie ^a   Görgens, Heike ^a   Mangold, Elisabeth ^c   Pagenstecher, Constanze ^c   Holinski Feder, Elke ^d   von Knebel Doeberitz, Magnus ^e   Royer Pokora, Brigitte ^f   Dechant, Stefan ^g   Pox, Christian ^h   Rahner, Nils ^c   Müller, Annegret ⁱ   Schackert, Hans K ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b UNIVERSITY OF LEIPZIG   (Germany)

^c UNIVERSITY OF BONN   (Germany)

^d UNIVERSITY OF MUNICH   (Germany)

^e UNIVERSITY OF HEIDELBERG   (Germany)

^f HEINRICH HEINE UNIVERSITY   (Germany)

^g UNIVERSITY OF REGENSBURG   (Germany)

^h RUHR UNIVERSITY BOCHUM   (Germany)

ⁱ UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Age of disease onset (AO); Hereditary nonpolyposis colorectal cancer (HNPCC); Mismatch repair (MMR) system; p53 Arg72Pro; RNASEL Arg462Gln

Indexed keywords

ARGININE; GLUTAMINE; PROLINE; PROTEIN MLH1; PROTEIN MSH2; PROTEIN P53; RIBONUCLEASE L;

APOPTOSIS; ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; FAMILIAL CANCER; FEMALE; GENE MUTATION; GENOTYPE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; TUMOR SUPPRESSOR GENE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADULT; AGE OF ONSET; AGED; AMINO ACID SUBSTITUTION; ARGININE; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; ENDORIBONUCLEASES; FEMALE; GENOTYPE; GERM-LINE MUTATION; HUMANS; MALE; MIDDLE AGED; MUTS HOMOLOG 2 PROTEIN; NUCLEAR PROTEINS; PROLINE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 34248356002     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2006.12.006     Document Type: Article

References (43)

1. Liu B., Parsons R., Papadopoulos N., Nicolaides N.C., Lynch H.T., Watson P., Jass J.R., Dunlop M., Wyllie A., Peltomaki P., de la Chapelle A., Hamilton S.R., Vogelstein B., and Kinzler K.W. Analysis of mismatch repair genes in hereditary non-polyposis colorectal cancer patients. Nat. Med. 2 (1996) 169-174
2. Ionov Y., Peinado M.A., Malkhosyan S., Shibata D., and Perucho M. Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature 363 (1993) 558-561
3. Lynch H.T., Smyrk T.C., Watson P., Lanspa S.J., Lynch J.F., Lynch P.M., Cavalieri R.J., and Boland C.R. Genetics, natural history, tumour spectrum, and pathology of hereditary nonpolyposis colorectal cancer: an updated review. Gastroenterology 104 (1993) 1535-1549
4. Vasen H.F., Wijnen J.T., Menko F.H., Kleibeuker J.H., Taal B.G., Griffioen G., Nagengast F.M., Meijers-Heijboer E.H., Bertario L., Varesco L., Bisgaard M.L., Mohr J., Fodde R., and Khan P.M. Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis. Gastroenterology 110 (1996) 1020-1027
5. Vasen H.F., Stormorken A., Menko F.H., Nagengast F.M., Kleibeuker J.H., Griffioen G., Taal B.G., Moller P., and Wijnen J.T. MSH2 mutation carriers are at higher risk of cancer than MLH1 mutation carriers: a study of hereditary nonpolyposis colorectal cancer families. J. Clin. Oncol. 19 (2001) 4074-4080
6. Storey A., Thomas M., Kalita A., Harwood C., Gardiol D., Mantovani F., Breuer J., Leigh I.M., Matlashewski G., and Banks L. Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature 393 (1998) 229-234
7. Birgander R., Sjalander A., Rannug A., Alexandrie A.K., Sundberg M.I., Seidegard J., Tornling G., Beckman G., and Beckman L. P53 polymorphisms and haplotypes in lung cancer. Carcinogenesis 16 (1995) 2233-2236
8. Sjalander A., Birgander R., Athlin L., Stenling R., Rutegard J., Beckman L., and Beckman G. P53 germ line haplotypes associated with increased risk for colorectal cancer. Carcinogenesis 16 (1995) 1461-1464
9. Josefsson A.M., Magnusson P.K., Ylitalo N., Quarforth-Tubbin P., Ponten J., Adami H.O., and Gyllensten U.B. p53 polymorphism and risk of cervical cancer. Nature 396 (1998) 531
10. Zehbe I., Voglino G., Wilander E., Genta F., and Tommasino M. Codon 72 polymorphism of p53 and its association with cervical cancer. Lancet 354 (1999) 218-219
11. Dumont P., Leu J.I., Della Pietra III A.C., George D.L., and Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat. Genet. 33 (2003) 357-365
12. Cranston A., Bocker T., Reitmair A., Palazzo J., Wilson T., Mak T., and Fishel R. Female embryonic lethality in mice nullizygous for both Msh2 and p53. Nat. Genet. 17 (1997) 114-118
13. Vikhanskaya F., Colella G., Valenti M., Parodi S., D'Incalci M., and Broggini M. Cooperation between p53 and hMLH1 in a human colocarcinoma cell line in response to DNA damage. Clin. Cancer. Res. 5 (1999) 937-941
14. Lin X., Ramamurthi K., Mishima M., Kondo A., Christen R.D., and Howell S.B. P53 modulates the effect of loss of DNA mismatch repair on the sensitivity of human colon cancer cells to the cytotoxic and mutagenic effects of cisplatin. Cancer Res. 61 (2001) 1508-1516
15. Toft N.J., Curtis L.J., Sansom O.J., Leitch A.L., Wyllie A.H., te Riele H., Arends M.J., and Clarke A.R. Heterozygosity for p53 promotes microsatellite instability and tumourigenesis on a Msh2 deficient background. Oncogene 21 (2002) 6299-6306
16. Kruger S., Bier A., Engel C., Mangold E., Pagenstecher C., von Knebel Doeberitz M., Holinski-Feder E., Moeslein G., Schulmann K., Plaschke J., Rüschoff J., Schackert H.K., and and The German HNPCC-Consortium. The p53 codon 72 variation is associated with the age of onset of hereditary non-polyposis colorectal cancer (HNPCC). J. Med. Genet. 42 (2005) 769-773
17. Hassel B.A., Zhou A., Sotomayor C., Maran A., and Silverman RH. A dominant negative mutant of 2-5A-dependent RNase suppresses antiproliferative and antiviral effects of interferon. EMBO J. 12 (1993) 3297-3304
18. Lengyel P. Tumor-suppressor genes: news about the interferon connection. Proc. Natl. Acad. Sci. USA 90 (1993) 5893-5895
19. Silverman R.H. Implications for RNase L in prostate cancer biology. Biochemistry 42 (2003) 1805-1812
20. Xiang Y., Wang Z., Murakami J., Plummer S., Klein E.A., Carpten J.D., Trent J.M., Isaacs W.B., Casey G., and Silverman R.H. Effects of RNase L mutations associated with prostate cancer on apoptosis induced by 2′,5′-oligoadenylates. Cancer Res. 63 (2003) 6795-6801
21. Carpten J., Nupponen N., Isaacs S., Sood R., Robbins C., Xu J., Faruque M., Moses T., Ewing C., Gillanders E., Hu P., Bujnovszky P., Makalowska I., Baffoe-Bonnie A., Faith D., Smith J., Stephan D., Wiley K., Brownstein M., Gildea D., Kelly B., Jenkins R., Hostetter G., Matikainen M., Schleutker J., Klinger K., Connors T., Xiang Y., Wang Z., De Marzo A., Papadopoulos N., Kallioniemi O.P., Burk R., Meyers D., Gronberg H., Meltzer P., Silverman R., Bailey-Wilson J., Walsh P., Isaacs W., and Trent J. Germline mutations in the ribonuclease L gene in families showing linkage with HPC1. Nat. Genet. 30 (2002) 181-184
22. Rennert H., Bercovich D., Hubert A., Abeliovich D., Rozovsky U., Bar-Shira A., Soloviov S., Schreiber L., Matzkin H., Rennert G., Kadouri L., Peretz T., Yaron Y., and Orr-Urtreger A. A novel founder mutation in the RNASEL gene, 471delAAAG, is associated with prostate cancer in Ashkenazi Jews. Am. J. Hum. Genet. 71 (2002) 981-984
23. Rokman A., Ikonen T., Seppala E.H., Nupponen N., Autio V., Mononen N., Bailey-Wilson J., Trent J., Carpten J., Matikainen M.P., Koivisto P.A., Tammela T.L., Kallioniemi O.P., and Schleutker J. Germline alterations of the RNASEL gene, a candidate HPC1 gene at 1q25, in patients and families with prostate cancer. Am. J. Hum. Genet. 70 (2002) 1299-1304
24. Casey G., Neville P.J., Plummer S.J., Xiang Y., Krumroy L.M., Klein E.A., Catalona W.J., Nupponen N., Carpten J.D., Trent J.M., Silverman R.H., and Witte J.S. RNASEL Arg462Gln variant is implicated in up to 13% of prostate cancer cases. Nat. Genet. 32 (2002) 581-583
25. Wiklund F., Jonsson B.A., Brookes A.J., Stromqvist L., Adolfsson J., Emanuelsson M., Adami H.O., Augustsson-Balter K., and Gronberg H. Genetic analysis of the RNASEL gene in hereditary, familial, and sporadic prostate cancer. Clin. Cancer Res. 10 (2004) 7150-7156
26. Rennert H., Zeigler-Johnson C.M., Addya K., Finley M.J., Walker A.H., Spangler E., Leonard D.G., Wein A., Malkowicz S.B., and Rebbeck T.R. Association of susceptibility alleles in ELAC2/HPC2, RNASEL/HPC1, and MSR1 with prostate cancer severity in European American and African American men. Cancer Epidemiol. Biomarkers Prev. 14 (2005) 949-957
27. Orr-Urtreger A., Bar-Shira A., Bercovich D., Matarasso N., Rozovsky U., Rosner S., Soloviov S., Rennert G., Kadouri L., Hubert A., Rennert H., and Matzkin H. RNASEL mutation screening and association study in Ashkenazi and non-Ashkenazi prostate cancer patients. Cancer Epidemiol. Biomarkers Prev. 15 (2006) 474-479
28. Kruger S., Silber A.S., Engel C., Görgens H., Mangold E., Pagenstecher C., Holinski-Feder E., von Knebel Doeberitz M., Moeslein G., Dietmaier W., Stemmler S., Friedl W., Rüschoff J., Schackert H.K., and for the German Hereditary Non-Polyposis Colorectal Cancer (HNPCC) Consortium. Arg462Gln sequence variation in the prostate-cancer-susceptibility gene RNASEL and age of onset of hereditary non-polyposis colorectal cancer: a case-control study. Lancet Oncol. 6 (2005) 566-572
29. Rodriguez-Bigas M.A., Boland C.R., Hamilton S.R., Henson D.E., Jass J.R., Khan P.M., Lynch H., Perucho M., Smyrk T., Sobin L., and Srivastava S. A National Cancer Institute Workshop on Hereditary Nonpolyposis Colorectal Cancer Syndrome: meeting highlights and Bethesda guidelines. J. Natl. Cancer Inst. 89 (1997) 1758-1762
30. Umar A., Boland C.R., Terdiman J.P., Syngal S., de la Chapelle A., Ruschoff J., Fishel R., Lindor N.M., Burgart L.J., Hamelin R., Hamilton S.R., Hiatt R.A., Jass J., Lindblom A., Lynch H.T., Peltomaki P., Ramsey S.D., Rodriguez-Bigas M.A., Vasen H.F., Hawk E.T., Barrett J.C., Freedman A.N., and Srivastava S. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J. Natl. Cancer Inst. 96 (2004) 261-268
31. Vasen H.F., Watson P., Mecklin J.P., and Lynch H. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology 116 (1999) 1453-1456
32. Kruger S., Bier A., Plaschke J., Hohl R., Aust D.E., Kreuz F.R., Pistorius S.R., Saeger H.D., Rothhammer V., Al-Taie O., and Schackert H.K. Ten novel MSH2 and MLH1 germline mutations in families with HNPCC. Hum. Mutat. 24 (2004) 351-352
33. Muller A., Giuffre G., Edmonston T.B., Mathiak M., Roggendorf B., Heinmoller E., Brodegger T., Tuccari G., Mangold E., Buettner R., and Ruschoff J. German HNPCC Consortium German Cancer Aid (Deutsche Krebshilfe), Challenges and pitfalls in HNPCC screening by microsatellite analysis and immunohistochemistry. J. Mol. Diagn. 6 (2004) 308-315
34. Mangold E., Pagenstecher C., Friedl W., Mathiak M., Büttner R., Engel C., Löffler M., Holinski-Feder E., Müller-Koch Y., Keller G., Schackert H.K., Kruger S., Goecke T., Möslein G., Kloor M., Gebert J., Kunstmann E., Schulmann K., Rüschoff J., Propping P., and and the German HNPCC Consortium. Spectrum and Frequencies of Mutations in MSH2 and MLH1 identified in 1721 German Families suspected of Hereditary Nonpolyposis Colorectal Cancer. Int. J. Cancer 116 (2005) 692-702
35. Lehman T.A., Bennett W.P., Metcalf R.A., Welsh J.A., Ecker J., Modali R.V., Ullrich S., Romano J.W., Appella E., and Testa J.R. p53 mutations, ras mutations, and p53-heat shock 70 protein complexes in human lung carcinoma cell lines. Cancer Res. 51 (1991) 4090-4096
36. Kristensen T., Kristensen V.N., and Borresen-Dale A.L. High-throughput screening for known mutations by automated analysis of single sequencing reactions. Biotechniques 24 (1998) 832-835
37. Farrington S.M., McKinley A.J., Carothers A.D., Cunningham C., Bubb V.J., Sharp L., Wyllie A.H., and Dunlop M.G. Evidence for an age-related influence of microsatellite instability on colorectal cancer survival. Int. J. Cancer 98 (2002) 844-850
38. Frazier M.L., O'Donnell F.T., Kong S., Gu X., Campos I., Luthra R., Lynch P.M., and Amos C.I. Age-associated risk of cancer among individuals with N-acetyltransferase 2(NAT2) mutations and mutations in DNA mismatch repair genes. Cancer Res. 61 (2001) 1269-1271
39. Kong S., Amos C.I., Luthra R., Lynch P.M., Levin B., and Frazier M.L. Effects of cyclin D1 polymorphism on age of onset of hereditary nonpolyposis colorectal cancer. Cancer Res. 60 (2000) 249-252
40. Kruger S., Engel C., Bier A., Mangold E., Pagenstecher C., von Knebel Doeberitz M., Holinski-Feder E., Moeslein G., Keller G., Kunstmann E., Friedl W., Plaschke J., Rüschoff J., Schackert H.K., and The German HNPCC-Consortium. Absence of association between cyclin D1 (CCND1) G870A polymorphism and age of onset in hereditary nonpolyposis colorectal cancer. Cancer Lett. 236 (2005) 191-197
41. Bala S., and Peltomaki P. CYCLIN D1 as a genetic modifier in hereditary nonpolyposis colorectal cancer. Cancer Res. 61 (2001) 6042-6045
42. Levine A.J. p53, the cellular gatekeeper for growth and division. Cell 88 (1997) 323-331
43. Hainaut P., and Hollstein M. p53 and human cancer: the first ten thousand mutations. Adv. Cancer Res. 77 (2000) 81-137